NCCN胰腺癌临床实践指南(2023.V2版)更新解读
Updates and interpretations of the NCCN Clinical Practice Guide 2ed version 2023 on pancreatic adenocarcinoma
白睿 1孙备1
作者信息
- 1. 哈尔滨医科大学附属第一医院胰胆外科肝脾外科教育部重点实验室,黑龙江哈尔滨 150001
- 折叠
摘要
胰腺导管腺癌生物学行为不良、预后较差,如何规范诊疗以进一步提高术后生存率和长期生存质量是胰腺外科医生长久以来所面临的难题.美国国家综合癌症网络(NCCN)指南于2023年6月19日发表了本年度第2版胰腺癌诊治指南.相较于前版,新版指南做出如下更新:NALIRIFOX方案正式进入局部进展期和转移性胰腺癌的一线全身治疗中;功能状态评分细分为良好(0～1分),中等(2分)和较差(3～4分);以及某些新型药物纳入了胰腺癌靶向治疗的范畴,整体治疗趋于精准化、综合化、实效化.NCCN指南在全球范围内具有权威的影响力,期待未来更多循证医学证据的面世,从而使胰腺癌的治疗更加规范.
Abstract
Pancreatic ductal adenocarcinoma has poor biological behavior and poor prognosis.How to standardize its diagnosis and treatment to further improve postoperative survival rate and long-term quality of life is a challenge faced by pancreatic surgeons.The National Comprehensive Cancer Network(NCCN)guidelines released the second edition of pancreatic cancer diagnosis and treatment guidelines this year on June 19,2023.Compared with the previous version,the new version of the guidelines has made the following updates:the NALIRIFOX protocol has officially entered the first-line treatment of locally advanced and metastatic pancreatic cancer;the functional status score is divided into good(0-1),intermediate(2),and poor(3-4);some new drugs have been included in the scope of targeted treatment for pancreatic cancer,the overall treatment tends to be precise,comprehensive and effective.The NCCN guidelines wield authoritative influence globally and the anticipation for further evidence-based medicine to emerge in the future is expected to standardize the treatment of pancreatic cancer.
关键词
胰腺导管腺癌/美国国立综合癌症网络/精准医学Key words
pancreatic ductal adenocarcinoma/national comprehensive cancer network(NCCN)/precision medicine引用本文复制引用
基金项目
国家自然科学基金(82070658)
国家自然科学基金(82270665)
黑龙江省自然科学基金团队项目(TD2021H001)
出版年
2024
国家科技期刊平台
NSTL
万方数据